Replies to post #9637 on Organovo Holdings, Inc. (ONVO)

[RandolRocketman]

I am not surprised by this at all, considering the latest announcement:
Organovo said it plans to pursue a formal preclinical program, and that for patients in need of a liver transplant, no alternatives exist today. About 17,000 patients are on the U.S. liver transplant waiting list, and only 6,000 liver transplants are performed each year.
Going into clinical trials is EXPENSIVE!